Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06554873 · ClinicalTrials.gov registry record · Phase 3
Adaptive Use of Nicotine Substitution to Maintain Smoking Reduction/Abstinence in Nicotine Responders
A Phase 3 study, sponsored by Rose Research Center.
- Completed
- Registry status
- Phase 3
- Development phase
- 150
- Enrollment target
NCT06554873 is a Phase 3 study that has completed, run by Rose Research Center. The registered enrollment target is 150 participants.
The verdict
NCT06554873, a Phase 3 study, has completed, sponsored by Rose Research Center.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 150 participants
- Enrollment target
Study Summary
To determine whether smokers who initially respond (within 2 weeks) to nicotine products (including nicotine replacement therapy, e-cigarettes, nicotine pouches) by reducing their smoking by ≥50% can be successfully maintained on use of these noncombustible nicotine alternatives to cigarettes for 6 months, and whether this results in sustained smoking reduction/abstinence.
Interventions
- DRUG Nicoderm
- DRUG Nicorette 4Mg Chewing Gum
- DRUG Nicorette Lozenge Product
- OTHER NJOY e-cigarette
- OTHER on!
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2024-08-29 |
| Est. Completion | 2025-12-09 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06554873
The ClinicalTrials.gov registry entry for NCT06554873 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 150 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Rose Research Center, which has 11 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Nicoderm is the first listed.
NCT06554873 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06554873 about?
NCT06554873 is a clinical study titled "Adaptive Use of Nicotine Substitution to Maintain Smoking Reduction/Abstinence in Nicotine Responders". To determine whether smokers who initially respond (within 2 weeks) to nicotine products (including nicotine replacement therapy, e-cigarettes, nicotine pouches) by reducing their smoking by ≥50% can be successfully maintained on use of these noncombustible nicotine alternatives to cigarettes for 6 ...
What is the current status of trial NCT06554873?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 150 participants. The study started on 2024-08-29. Estimated completion is 2025-12-09.
What interventions are being tested in trial NCT06554873?
The interventions under investigation include: Nicoderm (DRUG), Nicorette 4Mg Chewing Gum (DRUG), Nicorette Lozenge Product (DRUG), NJOY e-cigarette (OTHER), on! (OTHER).
Who is sponsoring clinical trial NCT06554873?
This trial is sponsored by Rose Research Center, which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.